Irving Dark is a biometrics Subject Matter Expert with over 30 years of industry experience guiding drug, biologic, and medical device products successfully through the development process. Currently, he is on the Board of Directors of MMS, Founder/Managing Director of Sun Rock Partners, and an Affiliate Partner at Lindsay Goldberg.

Irving established the Clinical Research Services division at Cytel and served as Senior Vice President of Project Based Services for over 13 years. Prior to Cytel, he held senior leadership roles at Veristat, where he established and oversaw several core business units.

Earlier in his career, Irving held key positions at PAREXEL, where he managed Phase I – III clinical trials in the US, South America, Europe and Asia. Major therapeutic areas of projects included: lipid-lower agent (CRESTOR®), HIV (NELFINAVIR®), acromegaly (SOMATULINE®), and Stroke.

Irving has an in-depth knowledge of clinical development and biometrics, is co-author of numerous published clinical studies, and a DIA invited speaker. Irving holds Bachelor of Arts in Economics from the University of Rhode Island.

Suggested For You

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development